Inhibikase Therapeutics (IKT) Total Liabilities (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Total Liabilities data on file, last reported at $5.7 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 33.2% year-over-year to $5.7 million in Q1 2026; TTM through Mar 2026 was $5.7 million, a 33.2% decrease from a year earlier, with the FY2025 full-year figure at $8.3 million, up 122.33% from the prior year.
• Total Liabilities for Q1 2026 stood at $5.7 million, down from $8.3 million in the prior quarter.
• Over the last five years, Total Liabilities for IKT reached as high as $8.8 million in Q2 2025 and fell as low as $2.8 million in Q1 2023.
• Historically, Total Liabilities has averaged $4.9 million across 5 years, with a median of $4.3 million in 2024.
• Across the five-year window, Total Liabilities plunged 35.79% in 2023 and surged 135.9% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $3.9 million in 2022, then slipped by 9.54% to $3.5 million in 2023, then advanced by 5.8% to $3.7 million in 2024, then soared by 122.33% to $8.3 million in 2025, then sank by 31.19% to $5.7 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $5.7 million in Q1 2026, $8.3 million in Q4 2025, and $6.7 million in Q3 2025.